Jacobs Levy Equity Management
LXRX icon

Jacobs Levy Equity Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130,020
Closed -$203K – 1023
2026
Q1 		$203K Buy
+130,020
New +$189K ﹤0.01% 918
2025
Q4 		– Sell
-692,727
Closed -$935K – 1006
2025
Q3 		$935K Buy
+692,727
New +$786K ﹤0.01% 734
2020
Q3 		– Sell
-219,311
Closed -$438K – 1072
2020
Q2 		$438K Sell
219,311
-186,827
-46% -$366K ﹤0.01% 815
2020
Q1 		$792K Buy
406,138
+36,895
+10% +$110K 0.01% 681
2019
Q4 		$1.53M Sell
369,243
-215,061
-37% -$828K 0.02% 592
2019
Q3 		$1.76M Buy
584,304
+486,662
+498% +$1.51M 0.02% 538
2019
Q2 		$614K Sell
97,642
-70,123
-42% -$420K 0.01% 710
2019
Q1 		$933K Sell
167,765
-79,325
-32% -$482K 0.01% 678
2018
Q4 		$1.64M Buy
247,090
+73,760
+43% +$598K 0.03% 503
2018
Q3 		$1.85M Buy
173,330
+2,223
+1% +$25.5K 0.03% 536
2018
Q2 		$2.05M Buy
171,107
+81,463
+91% +$833K 0.03% 506
2018
Q1 		$768K Sell
89,644
-54,495
-38% -$504K 0.01% 694
2017
Q4 		$1.42M Buy
+144,139
New +$1.5M 0.03% 540
2015
Q3 		– Sell
-28,054
Closed -$226K – 844
2015
Q2 		$226K Sell
28,054
-64,143
-70% -$471K ﹤0.01% 707
2015
Q1 		$609K Sell
92,197
-68,951
-43% -$471K 0.01% 562
2014
Q4 		$1.03M Buy
+161,148
New +$1.3M 0.02% 496

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jacobs Levy Equity Management's LXRX Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 130,020 shares — an estimated $203K sold.

Jacobs Levy Equity Management first reported a position in LXRX in Q4 2014 and held it in 16 quarters. The position peaked at $2.05M in Q2 2018. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 130,020 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $203K.
  • Jacobs Levy Equity Management first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 16 quarters.
  • Jacobs Levy Equity Management's Lexicon Pharmaceuticals position peaked at $2.05M in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.